N4 Pharma’s Nuvec® platform has been independently appraised by Dr. Amy S. Rosenberg, Senior Director of Immunology and Protein Therapeutics at EpiVax. In the report Dr. Rosenberg assesses how N4 Pharma’s breakthrough Nuvec® platform might address the current shortcomings in cancer therapy. The novel silica nanoparticle delivery system can [...]
Our research partners at Brunel University London found that adenovirus (Av) – an effective gene delivery vehicle for vaccinations – complexed with Nuvec®, can significantly improve adenovirus transduction. In the study, researchers investigated the effect of using Nuvec to improve Av gene transfer. To identify the optimal concentration [...]
N4 Pharma is pleased to announce the acquisition of a controlling interest, through a subscription for new ordinary shares, in Nanogenics Limited, a company with a complementary lipid and peptide-based delivery system called LipTide®, which it is using to develop a novel siRNA product targeting an unmet clinical need in [...]
The University of Queensland has announced that Professor Chengzhong Yu, Senior Group Leader, Australian Institute for Bioengineering and Nanotechnology (AIBN) has been awarded a $402,115 grant to develop an improved nanoparticle delivery system that enhances the performance of messenger ribonucleic acid (mRNA) therapies. The new nanoparticle will be based [...]
Our new animation displays how Nuvec’s® unique spiky structure and large surface area allow it to efficiently load, protect and deliver multiple siRNA to a target cell through endocytosis. Once delivered to the cytoplasm, the siRNA binds to the RNA-inducing silencing complex (RISC) to cut and degrade the specific [...]
In our latest article, we look at how Nuvec® offers an alternative to current drug delivery approaches for small interfering RNA (siRNA). Not only is Nuvec® particularly suited to chemical modification, allowing the addition of target specific ligands to receptors on cancer cells, but it may offer the convenience of [...]
As a result of recently completed initial testing in vitro on loaded Nuvec® with two generic siRNA probes, N4 Pharma has created an infographic outlining the key results and detailing how Nuvec® works to deliver multiple siRNA into the same cell. With siRNA increasingly being used in the development [...]
Ultrasound sonication is a well-established mechanism for the deagglomeration of particle materials in dispersion. In this recently published paper, the National Physical Laboratory investigates the deagglomeration of Nuvec® silica particles with and without the presence of plasmid via controlled sonication. It evaluated the performance of controlled cavitation using different [...]
In collaboration with Nanomerics Ltd, N4 Pharma has released the results of a recent study assessing the potential of Nuvec® , a non-viral nanoparticle delivery system consisting of poly(ethylenimine) coated silica particles, as a gene therapy delivery platform in cancer treatment. Introducing exogenous genetic material to a cell alters [...]
N4 Pharma highlights the potential of Nuvec® as a gene therapy delivery platform by successfully completing a pre-clinical, in-vivo oncology study. The results reinforce the findings from an earlier pilot study designed to test the ability to use a monodispersed Nuvec® formulation in an intravenous (“i.v”) route of administration using [...]
